Kolon Ramps Up For Novel Osteoarthritis Cell Therapy
This article was originally published in PharmAsia News
South Korea's Kolon Life Science is gearing up for mass production of Invossa, the world's first cell-mediated gene therapy for osteoarthritis, as it prepares to file for a domestic approval and a US Phase III study. The venture also plans to raise around $114m to hike its biologics production capacity.
You may also be interested in...
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.